We are live on ! Find out more
PIM

Ponoi II Management Portfolio holdings

AUM $38.3M
1-Year Est. Return 32.02%
This Fund
S&P 500
This Quarter Est. Return
-8.05%
1 Year Est. Return
-32.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$55.1M
AUM Growth
-$12.4M
Cap. Flow
-$7.11M
Cap. Flow %
-12.91%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$23M 41.78%
1,298,908
– –
RVMD icon
2
Revolution Medicines
RVMD
$39.6B
$17.2M 31.32%
685,011
– –
NRIX icon
3
Nurix Therapeutics
NRIX
$2.4B
$9.47M 17.2%
327,123
-234,451
-42% -$7.11M
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$5.34M 9.7%
18,175
– –

Similar funds

FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
PSCM
Prince Street Capital Management New York $40.3M AUM 0.66% 1-Year Est. Return

Ponoi II Management's Q4 2021 Portfolio in Review

As of Q4 2021, Ponoi II Management held 4 positions worth $55.1M, down 18% from $67.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Ponoi II Management withdrew a net $7.11M in Q4 2021, reducing 1 holding. Its largest reduction was Nurix Therapeutics, cutting an estimated $7.11M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Ponoi II Management's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $7.11M.
  • Ponoi II Management's ten largest holdings make up 100% of its $55.1M portfolio in Q4 2021.
  • Ponoi II Management opened 0 new positions and closed 0 in Q4 2021.
  • Ponoi II Management's portfolio value fell 18% quarter-over-quarter to $55.1M.

Based on Ponoi II Management's 13F filing for Q4 2021, filed 11 Feb 2022.